24 . November , 2017 - Friday
Check todays hot topics or new products

Find a Drug: Advanced

Please Sign in or Register

All about: Argatroban

Big Image Pronouncation: (ahr-GAT-troe-ban)
Class: Thrombin inhibitor

Trade Names:
- Injection 100 mg/mL

Mechanism of Action


Binds reversibly to thrombin active site, exerting its anticoagulant effects by inhibiting thrombin-catalyzed or induced reactions, including activation of coagulation factors V, VIII, and XIII, protein C, and platelet aggregation.



Distributes mainly in the extracellular fluid. Vd is 174 mL/kg. Approximately 54% is protein bound (20% to albumin and 34% to alpha-1-glycoprotein).


Hydroxylation and aromatization in the liver. CYP3A4/5 plays a minor role.


Cl is approximately 5.1 mL/kg/min; t ½ is 39 to 51 min. Approximately 65% is excreted in the feces (through biliary secretion) and approximately 22% is excreted in the urine. At least 14% is recovered in the feces as unchanged drug and 16% in urine.




1 to 3 h (steady state).

Special Populations

Hepatic Function Impairment

Cl is reduced and t ½ is increased. Dosage adjustment is recommended.

Indications and Usage

As an anticoagulant for prophylaxis and treatment of thrombosis in heparin-induced thrombocytopenia (HIT); as an anticoagulant in patients with or at risk for heparin-induced thrombocytopenia undergoing percutaneous coronary intervention (PCI).


Overt major bleeding; hypersensitivity to this product or any component of this product.

Dosage and Administration

Coadministration of Warfarin
Adults (receiving argatroban up to 2 mcg/kg/min)

Measure international normalized ratio (INR) daily during coadministration of argatroban and warfarin. In general, doses of argatroban up to 2 mcg/kg/min can be discontinued when the INR is greater than 4. Repeat INR 4 to 6 h after stopping argatroban and, if the INR is below desired therapeutic range, resume argatroban infusion and repeat the procedure daily until desired therapeutic range on warfarin alone is achieved.

Adults (receiving argatroban at doses greater than 2 mcg/kg/min)

Temporarily reduce dose of argatroban to 2 mcg/kg/min and repeat the INR on argatroban and warfarin 4 to 6 h after reducing the argatroban dose; follow the process described above for administering warfarin and argatroban at doses up to 2 mcg/kg/min.

Hepatic Function Impairment

IV In patients with moderate hepatic function impairment, initial dose is 0.5 mcg/kg/min; monitor aPTT closely and adjust dose as clinically indicated.

HIT or Heparin-Induced Thrombocytopenia and Thrombosis Syndrome (HITTS)

IV Initial dose is 2 mcg/kg/min as a continuous infusion; after initial dose, the dose can be adjusted as clinically indicated (not exceeding 10 mcg/kg/min), until steady-state activated partial thromboplastin time (aPTT) is 1.5 to 3 times the initial baseline value (not to exceed 100 sec).


IV Initial dose is 25 mcg/kg/min and bolus of 350 mcg/kg via large bore IV line administered over 3 to 5 min. Check activated clotting time (ACT) 5 to 10 min after bolus is completed. Proceed if ACT is greater than 300 sec. If ACT is less than 300 sec, administer an additional IV bolus dose of 150 mcg/kg, increase the infusion dose to 30 mcg/kg/min, and check the ACT 5 to 10 min later. If ACT is greater than 450 sec, decrease the infusion rate to 15 mcg/kg/min and check ACT 5 to 10 min later. Once ACT is between 300 and 450 sec, continue infusion dose for the duration of the procedure. In case of dissection, impending abrupt closure, thrombus formation during the procedure, or inability to achieve or maintain an ACT over 300 sec, additional bolus doses of 150 mcg/kg may be administered and the infusion dose increased to 40 mcg/kg/min. Check the ACT after each additional bolus or change in rate of infusion.

General Advice

  • Follow manufacturer's guidelines for diluting concentrated solution in sodium chloride 0.9% injection, dextrose 5% injection, or Ringer's lactate injection before infusing.
  • Do not mix with other injections or infusions.
  • Do not administer if particulate matter or discoloration noted.


Store vials at controlled room temperature (59° to 86°F). Diluted solution can be kept at room temperature for up to 24 h or in refrigerator (36° to 46°F) for up to 48 h. Do not freeze or expose to direct sunlight.

Drug Interactions

Anticoagulants, antiplatelet agents, thrombolytics

May increase risk of bleeding.


Allow sufficient time for effects of heparin on aPTT to decrease before starting argatroban therapy.

Laboratory Test Interactions

None well documented.

Adverse Reactions


Hypotension (11%); cardiac arrest (6%); ventricular tachycardia, bradycardia (5%); MI (4%); atrial fibrillation (3%); cerebrovascular disorder, coronary thrombosis, myocardial ischemia, coronary occlusion, angina pectoris (2%); aortic stenosis, arterial thrombosis, cerebrovascular disorder, vascular disorder (1%).


Headache (5%).


Allergic skin reactions (including rash, bullous eruption; 1% to less than 10%).


Minor hemorrhagic GI bleeding (14%); nausea (7%); diarrhea, vomiting (6%); abdominal pain (3%); major hemorrhagic GI bleeding (2%); gastroesophageal reflux disease (1%).


Minor GU hemorrhage and hematuria (12%); UTI (5%); abnormal renal function (3%); major GU hemorrhage and hematuria (1%).


Minor decrease in hemoglobin and hematuria (12%); sepsis (6%); overall bleeding (hemorrhagic [5%]); retroperitoneal hemorrhage, major decrease in hemoglobin and hematocrit (1%).


Hemoptysis, pneumonia (3%); lung edema (1%).


Allergic airway reactions (including coughing and dyspnea [10% or more]); dyspnea (8%); coughing (3%).


Chest pain (15%); back pain (8%); minor hemorrhagic event/groin, pain (5%); infection, fever (4%); minor hemorrhagic event/brachial (2%); general allergic reactions (1% to less than 10%).



Active clotting time (ACT)

Determine ACT prior to removal of arterial sheath. Do not remove sheath until ACT is less than 160 sec.


Monitor patient for signs of bleeding, especially at vascular access sites, throughout therapy. If excessive or unusual bruising develops, or if bleeding develops (eg, epistaxis, hematuria, hematemesis, bloody or black, tarry stools) or is suspected (eg, unexplained fall in hematocrit or BP, or any other unexplained symptom develops), notify health care provider immediately.


Ensure baseline hematocrit or hemoglobin and platelet count are obtained and evaluated prior to starting therapy.


Category B .




Safety and efficacy not established.

Hepatic Function

Use with caution.


Because hemorrhage can occur at any site in patients receiving argatroban, use with extreme caution in disease states or circumstances in which there is an increased danger of hemorrhage (eg, major surgery, severe hypertension, spinal anesthesia).

Parenteral anticoagulants

Ensure all parenteral anticoagulants have been discontinued before administering argatroban.



Excessive anticoagulation.

Patient Information

  • Advise patient, family, or caregiver that medication will be prepared and administered by health care professional in a hospital setting.
  • Instruct patient, family, or caregiver to report any of the following immediately: bleeding or unusual bruising, coughing, difficulty breathing, skin rash or reaction.

Recent Drug Updates at DrugIndexOnline:

Blistex Medicated Lip Conditioner Topical Blistex Medicated Lip Conditioner Topical
Some commonly used brand names are: In the U.S.— A-Fil 33 Aquaderm Sunscreen Moisturizer 49 Aquaray Sunscreen 42 Bain de Soleil All Day For Kids 38 Bain de Soleil All Day Sunfilter 39 Bain de Soleil Mega Tan 34 Bain de Soleil Orange Gelee 41 Bain de Soleil Sand Buster 41 Bain de Soleil SP more...

Butorphanol Solution Butorphanol Solution
Generic Name: Butorphanol Nasal Solution (byoo-TOR-fan-ahl) Brand Name: Generic only. No brands available.Butorphanol Solution is used for:Relieving headache or pain due to surgery, labor, or other causes. It may also be used for other conditions as determined by your doctor. Butorphanol Solution more...

Cardizem CD Cardizem CD
Generic Name: diltiazem (dil TYE a zem) Brand Names: Cardizem, Cardizem CD, Cardizem LA, Cardizem SR, Cartia XT, Dilacor XR, Diltia XT, Tiazac What is Cardizem CD (diltiazem)? Diltiazem is in a group of drugs called calcium channel blockers. It works by relaxing the muscles of your hear more...

Daunorubicin Daunorubicin
Generic Name: Daunorubicin (daw-noe-ROO-bi-sin) Brand Name: CerubidineDaunorubicin can cause tissue damage if it is injected by a route other than through the vein. Notify your doctor immediately if redness, pain, and swelling occur at or around the injection site. Daunorubicin may cause heart more...

Hyoscyamine Hyoscyamine
Generic Name: Hyoscyamine Injection (hye-oh-SYE-a-meen) Brand Name: LevsinHyoscyamine is used for:Treating certain stomach or bowel problems (eg, ulcers, spasms or cramping, irritable bowel syndrome, symptoms of colic), certain bladder problems (eg, spastic bladder, cystitis), and excessive sec more...

Marax Marax
Some commonly used brand names are: In the U.S.— Marax Marax-DF † Not commercially available in Canada. Category Bronchodilator Description Theophylline, ephedrine , and hydroxyzine (thee-OFF-i-lin, e-FED-rin, and hye-DROX-i-zeen) combination medicine is used to treat or p more...

Mumps Virus Vaccine Mumps Virus Vaccine
Generic Name: Mumps Virus Vaccine (Mumps) Brand Name: MumpsvaxMumps Virus Vaccine is used for:Providing protection (immunity) against mumps infection in persons 12 months of age and older. Mumps Virus Vaccine is a vaccine. It works by stimulating the body to create antibodies, which provide pr more...

Neutra-Phos Neutra-Phos
Generic Name: potassium phosphate and sodium phosphate (poe TASS ee um FOSS fate and SEW dee um FOSS fate) Brand Names: K-Phos M.F., K-Phos Neutral, K-Phos No. 2, Neutra-Phos, Uro-KP-Neutral What are Neutra-Phos (potassium phosphate and sodium phosphate)? Phosphorus is a naturally occur more...